More articles from 5.1 Airway Pharmacology and Treatment

Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients
Fabrizia Mariotti, Sara Collarini, Stefano Vezzoli, Daniela Acerbi, Maxim Kots, Piotr Kuna

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4064; DOI: 10.1183/13993003.congress-2016.PA4064
Direct cost analysis of COPD patients: A 1 year follow-up study
Ünal Akel, Süleyman Savas Hacievliyagil, Zeynep Ayfer Aytemur, Saim Yologlu, Saltuk Bugra Kaya, Nazan Akel

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4070; DOI: 10.1183/13993003.congress-2016.PA4070
Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen complexity index
Wei Erh Cheng, Shan Chieh Wu, Sandy Ian-U. Chong, Jou Ying Chen, Hsiang-Wen Lin

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4061; DOI: 10.1183/13993003.congress-2016.PA4061
Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis
Daniel Dusser, Peter M.A. Calverley, Robert A. Wise, Achim Mueller, Norbert Metzdorf, Antonio Anzueto

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4083; DOI: 10.1183/13993003.congress-2016.PA4083
The effect of aclidinium bromide 400 µg on sleep quality in COPD: A pilot study
Helgo Magnussen, Michael Arzt, Stefan Andreas, Tanja Plate, Anna Ribera, Beatriz Seoane, Henrik Watz, Anne-Marie Kirsten

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4051; DOI: 10.1183/13993003.congress-2016.PA4051
Total and free IgE in evolution of severe asthma after omalizumab treatment
María del Carmen Vennera, Mariona Pascal, Ebymar Arismendi Nunez, César Picado

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4117; DOI: 10.1183/13993003.congress-2016.PA4117
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone
Luigino Calzetta, Paola Rogliani, Ermanno Puxeddu, Josuel Ora, Francesco Facciolo, Maria Gabriella Matera, Mario Cazzola

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4090; DOI: 10.1183/13993003.congress-2016.PA4090
Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials
John R. Hurst, Samy Suissa, Klaus F. Rabe, Giovanni Bader, Gerrit Zijlstra, Marcela Gavornikova, Francesco Patalano, Robert Fogel, Konstantinos Kostikas

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4062; DOI: 10.1183/13993003.congress-2016.PA4062
SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Johann Christian Virchow, Victoria Cardona, Hanne Villesen, Christian Ljørring, Bente Riis, Frederic de Blay

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4108; DOI: 10.1183/13993003.congress-2016.PA4108
Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Samy Suissa, Sophie Dell'Aniello, Pierre Ernst

European Respiratory Journal Sep 2016, 48 (suppl 60) PA4084; DOI: 10.1183/13993003.congress-2016.PA4084

Main menu

User menu

Search

More articles from 5.1 Airway Pharmacology and Treatment

Pages

Contact us